The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| PMVP | -11.95% | -96.01% | -47.47% | -96% |
| S&P | +17.35% | +108.64% | +15.84% | +107% |
PMV Pharmaceuticals, Inc. is a precision oncology company, which engages in the discovery and development of small molecule, tumor-agnostic therapies targeting p53. The company was founded by Arnold J. Levine, David Henry Mac, and Thomas E. Shenk in March 2013 and is headquartered in Princeton, NJ.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.03M | 91.4% |
| Market Cap | $55.07M | -33.9% |
| Market Cap / Employee | $1.17M | 0.0% |
| Employees | 47 | -25.4% |
| Net Income | -$21.21M | -1648.6% |
| EBITDA | -$22.85M | -15.4% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $44.13M | -10.6% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.64M | -94.6% |
| Short Term Debt | $0.38M | -67.2% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -41.43% | -21.1% |
| Return On Invested Capital | -23.62% | -1.5% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$18.31M | -1043.1% |
| Operating Free Cash Flow | -$18.30M | -1045.3% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.36 | 0.39 | 0.32 | 0.34 | -12.22% |
| Price to Tangible Book Value | 0.36 | 0.39 | 0.32 | 0.34 | -12.22% |
| Enterprise Value to EBITDA | 4.35 | 3.58 | 4.77 | 3.77 | -36.41% |
| Return on Equity | -23.6% | -29.2% | -32.7% | -45.6% | 101.44% |
| Total Debt | $13.27M | $1.19M | $1.11M | $1.02M | -92.15% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
